Bulli Padmaja Tadi

7704982, Apr 27, 2010

Jul 9, 2007

11/775117

Hector F. DeLuca - Deerfield WI, US
Bulli Padmaja Tadi - Madison WI, US
Lori A. Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07C 401/00

514167, 552653

This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

7741313, Jun 22, 2010

Jul 9, 2007

11/775108

Hector F. DeLuca - Deerfield WI, US
Bulli Padmaja Tadi - Madison WI, US
Lori A. Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07D 401/00

514167, 552653

This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin Dand pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy and obesity.

7888339, Feb 15, 2011

Jul 10, 2008

12/171056

Hector F. DeLuca - Deerfield WI, US
Bulli Padmaja Tadi - Madison WI, US
Lori A. Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07C 401/00

514167, 552653

This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1α,25-dihydroxyvitamin D, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

7893043, Feb 22, 2011

Jul 10, 2008

12/171071

Hector F. DeLuca - Deerfield WI, US
Bulli Padmaja Tadi - Madison WI, US
Lori A. Plum - Arena WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07C 401/00

514167, 552653

This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has significant calcemic activity in vivo having about the same bone calcium mobilization activity and intestinal calcium transport activity as the native hormone 1α,25-dihydroxyvitamin D, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

8222236, Jul 17, 2012

Jul 10, 2008

12/171045

Hector F. DeLuca - Deerfield WI, US
Bulli Padmaja Tadi - Madison WI, US
Lori A. Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07C 401/00

514167, 552653

This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-1α,25-dihydroxyvitamin D, and pharmaceutical uses therefore. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1α,25-dihydroxyvitamin D, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

8232263, Jul 31, 2012

Jul 9, 2007

11/775061

Hector F. DeLuca - Deerfield WI, US
Bulli Padmaja Tadi - Madison WI, US
Lori A. Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07D 401/00

514167, 552653

This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin Dand pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy and obesity. This compound also has significant calcemic activity making it a therapeutic agent for the treatment or prophylaxis of osteoporosis, osteomalacia, renal osteodystrophy and hypoparathyroidism.

20060111321, May 25, 2006

Nov 18, 2005

11/283125

Hector DeLuca - Deerfield WI, US
Bulli Tadi - Madison WI, US
Lori Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

A61K 31/695
A61K 31/59
C07C 401/00

514063000, 514167000, 552653000

This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

20060111330, May 25, 2006

Nov 18, 2005

11/283291

Hector DeLuca - Deerfield WI, US
Bulli Tadi - Madison WI, US
Lori Plum - Arena WI, US
Margaret Clagett-Dame - Deerfield WI, US

A61K 31/59
C07C 401/00

514167000, 552653000

This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin Dand pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy and obesity.